Partner since 2024: The Eyerising Myopia Management Device delivers repeated low-level red-light therapy to the back of the eye, where it stimulates blood flow and thickens the layer of the back of the eye known as the choroid. This helps to slow further elongation of the eye’s axial length and thereby control myopia progression. As the device is non-invasive and has a wide age range availability, it offers an opportunity to start treatment earlier and in children who are not willing to use or compliant with eye drops or contact lenses. Additionally, there is the option of using RLRL not only as standalone therapy but as adjunct therapy, where it has shown strong efficacy in patients not responding to conventional myopia treatments such as orthokeratology.